Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Supply of tocilizumab to NHS Scotland.
| Supplier | Identifier | Award Value | Lots Won | Cross-References |
|---|---|---|---|---|
| AbbVie Ltd | 08004972 | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | LOBBYIST Policy Connect Limited (15 quarters) WA Communications Ltd (3 quarters) Portland PR Limited (3 quarters) Incisive Health Ltd (1 quarter) Political Lobbying & Media Relations Limited (1 quarter) |
| Alexion Rare Disease part of Astra Zeneca | - | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | - |
| Amgen Ltd | 02354269 | ~£96,242,448 estimated from lot values | 1 lot NP47923a Adalimumab | - |
| Biogen Idec Ltd | 01497267 | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | LOBBYIST Portland PR Limited (2 quarters) Hawthorn Advisors Limited (1 quarter) |
| Celltrion Healthcare United Kingdom Limited | 11685363 | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | - |
| Fresenius Kabi Limited | 02182135 | ~£96,242,448 estimated from lot values | 1 lot NP47923a Adalimumab | - |
| Roche Products Ltd | 00100674 | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | LOBBYIST M&F Health (5 quarters) Ovid Consulting Ltd (2 quarters) |
| Samsung Bioepis | 08840722 | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | - |
| Sandoz | 01547204 | ~£48,121,224 estimated from lot values | 1 lot NP47923a Adalimumab | - |
This procurement was divided into 3 lots, each awarded separately. 11 bids were received in total.
| Lot | Value | Bids Received | Awarded To | Status |
|---|---|---|---|---|
| Lot 3 NP47923c Eculizumab 720 days (≈2 yrs) | £10,596,600 | - | - | active |
| Lot 2 NP47923b Tocilizumab 360 days | £35,297,308 | - | - | active |
| Lot 1 NP47923a Adalimumab 720 days (≈2 yrs) | £48,121,224 £83,673,821 initial term | 2 | AbbVie Ltd Amgen Ltd Biogen Idec Ltd Celltrion Healthcare United Kingdom Limited Fresenius Kabi Limited Sandoz Alexion Rare Disease part of Astra Zeneca Samsung Bioepis Roche Products Ltd | active |
Weightings from the notice, applied to every lot.
Government spending data: These suppliers have received £247,584,671 in 5,943 payments (over £25k) from NHS Supply Chain (DHSC-funded), Department of Health and Social Care, Manchester University NHS Foundation Trust, Royal Cornwall Hospitals NHS Trust, Guy's and St Thomas' NHS FT and 14 more public bodies (2010-08-03 to 2026-03-31).
Published by the buyer on this notice. Check the original notice — details change and are not updated here.